288 related articles for article (PubMed ID: 28655486)
1. Vaginal Atrophy in Breast Cancer Survivors: Attitude and Approaches Among Oncologists.
Biglia N; Bounous VE; D'Alonzo M; Ottino L; Tuninetti V; Robba E; Perrone T
Clin Breast Cancer; 2017 Dec; 17(8):611-617. PubMed ID: 28655486
[TBL] [Abstract][Full Text] [Related]
2. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.
Kingsberg SA; Larkin L; Krychman M; Parish SJ; Bernick B; Mirkin S
Menopause; 2019 Feb; 26(2):124-131. PubMed ID: 30130293
[TBL] [Abstract][Full Text] [Related]
3. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
4. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
5. Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.
Mariani L; Gadducci A; Vizza E; Tomao S; Vici P
Gynecol Endocrinol; 2013 Jan; 29(1):25-9. PubMed ID: 22994445
[TBL] [Abstract][Full Text] [Related]
6. Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel.
Biglia N; Del Pup L; Masetti R; Villa P; Nappi RE
Support Care Cancer; 2020 Jun; 28(6):2507-2512. PubMed ID: 31970513
[TBL] [Abstract][Full Text] [Related]
7. Management of genitourinary syndrome of menopause in breast cancer survivors: An update.
Lubián López DM
World J Clin Oncol; 2022 Feb; 13(2):71-100. PubMed ID: 35316932
[TBL] [Abstract][Full Text] [Related]
8. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
[TBL] [Abstract][Full Text] [Related]
9. Ospemifene, vulvovaginal atrophy, and breast cancer.
Wurz GT; Soe LH; DeGregorio MW
Maturitas; 2013 Mar; 74(3):220-5. PubMed ID: 23332519
[TBL] [Abstract][Full Text] [Related]
10. Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Pagano T; De Rosa P; Vallone R; Schettini F; Arpino G; De Placido S; Nazzaro G; Locci M; De Placido G
Menopause; 2016 Oct; 23(10):1108-13. PubMed ID: 27648595
[TBL] [Abstract][Full Text] [Related]
11. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.
Palacios S; Cancelo MJ; Castelo Branco C; Llaneza P; Molero F; Borrego RS
Climacteric; 2017 Feb; 20(1):55-61. PubMed ID: 28042734
[TBL] [Abstract][Full Text] [Related]
12. Vulvovaginal atrophy in women after cancer.
Cox P; Panay N
Climacteric; 2019 Dec; 22(6):565-571. PubMed ID: 31411904
[TBL] [Abstract][Full Text] [Related]
13. Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?
Biglia N; Bounous VE; Sgro LG; D'Alonzo M; Pecchio S; Nappi RE
Clin Breast Cancer; 2015 Dec; 15(6):413-20. PubMed ID: 26198332
[TBL] [Abstract][Full Text] [Related]
14. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
Nappi RE; Palacios S
Climacteric; 2014 Feb; 17(1):3-9. PubMed ID: 24423885
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women.
Nappi RE; Kotek M; Brešt'anský A; Giordan N; Tramentozzi E
Climacteric; 2020 Oct; 23(5):519-524. PubMed ID: 32396754
[No Abstract] [Full Text] [Related]
16. [Vaginal oestrogen therapy in women with hormone-sensitive breast cancer].
Bak AM; Laursen BE; Rungby J; Brock B
Ugeskr Laeger; 2011 Feb; 173(9):648-51. PubMed ID: 21362392
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study.
Hersant B; SidAhmed-Mezi M; Belkacemi Y; Darmon F; Bastuji-Garin S; Werkoff G; Bosc R; Niddam J; Hermeziu O; La Padula S; Meningaud JP
Menopause; 2018 Oct; 25(10):1124-1130. PubMed ID: 29738415
[TBL] [Abstract][Full Text] [Related]
18. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause.
Palacios S; Nappi RE; Bruyniks N; Particco M; Panay N;
Climacteric; 2018 Jun; 21(3):286-291. PubMed ID: 29553288
[TBL] [Abstract][Full Text] [Related]
19. Iranian postmenopausal women's experiences of treatment of symptomatic vulvovaginal atrophy.
Fooladi E; Deldar M; Mohammadzadeh F; Ahmadnia E; Khani S; Ghanbari Z
Climacteric; 2017 Feb; 20(1):67-71. PubMed ID: 28064523
[TBL] [Abstract][Full Text] [Related]
20. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.
Moegele M; Buchholz S; Seitz S; Ortmann O
Arch Gynecol Obstet; 2012 May; 285(5):1397-402. PubMed ID: 22212649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]